Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 3,104 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 3,104 shares of the stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $77.09, for a total value of $239,287.36. Following the transaction, the chief financial officer owned 108,065 shares of the company’s stock, valued at approximately $8,330,730.85. This represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Revolution Medicines Stock Performance

Shares of RVMD stock opened at $75.96 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.05 and a current ratio of 8.05. The firm has a market cap of $14.68 billion, a P/E ratio of -14.69 and a beta of 0.96. The firm’s 50 day moving average price is $66.12 and its 200-day moving average price is $48.95. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $81.49.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, November 5th. The company reported ($1.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same quarter in the prior year, the firm posted ($0.94) earnings per share. As a group, equities research analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Institutional Trading of Revolution Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC increased its holdings in shares of Revolution Medicines by 2.1% in the third quarter. Farallon Capital Management LLC now owns 14,625,692 shares of the company’s stock valued at $683,020,000 after purchasing an additional 300,000 shares during the period. Baker BROS. Advisors LP grew its position in Revolution Medicines by 1.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 9,455,357 shares of the company’s stock valued at $441,565,000 after buying an additional 90,385 shares during the last quarter. Nextech Invest Ltd. increased its stake in Revolution Medicines by 20.7% in the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock valued at $332,472,000 after buying an additional 1,304,347 shares during the period. Paradigm Biocapital Advisors LP raised its position in Revolution Medicines by 2.1% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,223,291 shares of the company’s stock worth $290,628,000 after buying an additional 130,000 shares during the last quarter. Finally, Bellevue Group AG lifted its stake in shares of Revolution Medicines by 21.7% in the 3rd quarter. Bellevue Group AG now owns 5,573,838 shares of the company’s stock worth $260,298,000 after acquiring an additional 994,538 shares during the period. 94.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on RVMD shares. Truist Financial began coverage on Revolution Medicines in a research note on Friday, September 5th. They set a “buy” rating and a $99.00 target price for the company. Raymond James Financial boosted their price objective on shares of Revolution Medicines from $72.00 to $76.00 and gave the stock a “strong-buy” rating in a research report on Friday, October 17th. Needham & Company LLC increased their target price on shares of Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Mizuho assumed coverage on shares of Revolution Medicines in a research note on Tuesday, October 21st. They set an “outperform” rating and a $90.00 price target on the stock. Finally, Royal Bank Of Canada started coverage on shares of Revolution Medicines in a research report on Monday, November 3rd. They issued an “outperform” rating and a $77.00 price target for the company. Four research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Revolution Medicines presently has a consensus rating of “Buy” and a consensus target price of $78.50.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.